Focus on zavegepant: the first intranasal third-generation gepant.

Area of Science:

• Pharmacology and Therapeutics
• Neurology
• Drug Development

Background:

• Migraine is a leading cause of disability, often exacerbated by calcitonin gene-related peptide (CGRP) pathway involvement.
• Gepants, CGRP receptor antagonists, represent a significant advancement in migraine pharmacotherapy, evolving from early hepatotoxic agents.
• Oral gepants like rimegepant, ubrogepant, and atogepant are approved with no hepatotoxicity warnings.

Purpose of the Study:

• To provide an overview of the novel, third-generation intranasal zavegepant.
• To discuss the development process of intranasal zavegepant.
• To explore future perspectives for intranasal zavegepant in migraine management.

Main Methods:

• Drug evaluation study.
• Review of developmental data for intranasal zavegepant.
• Analysis of the therapeutic class of gepants.

Main Results:

• Intranasal zavegepant represents the third generation of CGRP receptor antagonists.
• Developmental progression has led to improved safety profiles compared to earlier gepants.
• Long-term, real-world data on gepant efficacy and safety are still needed.

Conclusions:

• Intranasal zavegepant is a novel therapeutic option for migraine.
• Further postmarketing data will be crucial for understanding its long-term impact.
• The evolution of gepants highlights significant progress in targeted migraine therapy.